Sun Pharma has received a USFDA Consent Decree Correspondence Non Compliance Letter to its Mohali facility asking to take corrective actions before releasing products to U.S Read More.. It is pausing production at the facility. Sun Mohali facility was inspected by USFDA in Aug 2022 (Justin A Boyd, Teresa I Navas and Jonah S Ufferfilge) and issued USFDA 483 with six observations